Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
LETTERS TO THE EDITOR

First Isolation of blaVIM-2 in an Environmental Isolate of Pseudomonas pseudoalcaligenes

Sandra Quinteira, Helena Ferreira, Luísa Peixe
Sandra Quinteira
Instituto Politécnico da Saúde do Norte-ESSVA Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helena Ferreira
REQUIMTE Laboratório de Microbiologia Faculdade de Farmácia Rua Aníbal Cunha 164 4050-047 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luísa Peixe
REQUIMTE Laboratório de Microbiologia Faculdade de Farmácia Rua Aníbal Cunha 164 4050-047 Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lpeixe@ff.up.pt
DOI: 10.1128/AAC.49.5.2140-2141.2005
  • Article
  • Info & Metrics
  • PDF
Loading

Since the first description of VIM-2, in France, in a Pseudomonas aeruginosa clinical isolate (7), this enzyme has been detected in clinical Pseudomonas isolates in several countries (6), thus highlighting the need for a detailed knowledge of its spreading dynamics. In Portugal, since the first clinical isolate of blaVIM-2-producing P. aeruginosa, collected in 1995 (1), several carbapenemase producers have been recurrently observed in hospitals from the northern and central regions (8).

Concerns in the scientific community rapidly grew when, besides the rapid boost in the increase of this enzyme's geographical distribution area, VIM-2 started to be found in other species than P. aeruginosa, such as Pseudomonas putida, Pseudomonas stutzeri (11), and some Enterobacteriaceae (3, 4, 12). Nevertheless, all these isolates were found in the hospital setting, possibly suggesting a certain degree of confinement within this ecological niche. In this study we report the first environmentally isolated Pseudomonas pseudoalcaligenes carrying a metallo-β-lactamase (MBL).

P. pseudoalcaligenes E60 was recovered from a hospital wastewater-receiving urban sewage system, as a result of regular screening for MBL producers from several sources. Sampling procedure consisted of plating 100-μl aliquots of wastewater on MacConkey agar supplemented with imipenem (2 μg/ml). Samples were collected upstream and downstream from the point where hospital wastewaters were discharged in the sampled sewage. The identification of isolate E60 was based on the results of 16S rRNA sequencing. The MICs of β-lactams were determined by the Etest method (AB Biodisk, Solna, Sweden). The strain was resistant to carbapenems (MICs for imipenem and meropenem were >32 μg/ml) but was still susceptible to aztreonam (MIC, 2 μg/ml), ceftazidime (MIC, 8 μg/ml), cefepime (MIC, 4 μg/ml), piperacillin (MIC, 8 μg/ml), and piperacillin + tazobactam (MIC, 8 μg/ml). It was also susceptible to all four tested aminoglycosides (tobramycin, amikacin, gentamicin, and netilmicin) and to ciprofloxacin, tested by the disk diffusion method (5). The strain was positive by an MBL production screening test (1), and a multiplex PCR assay designed to amplify both the blaVIM and blaIMP genes (1, 10) was performed. Sequencing confirmed that this strain possessed blaVIM-2.

The metallo-β-lactamase determinant was not transferred to rifampin-resistant P. aeruginosa strain PAO or rifampin-resistant Escherichia coli strain K802N in mating experiments in solid media (9). These results suggested the chromosomal location of blaVIM which was later confirmed by total DNA digest with I-CeuI enzyme, its separation by pulsed-field gel electrophoresis, and hybridization with blaVIM-2 and rRNA probes, as described previously (9). Three chromosomal bands were visualized after I-CeuI digestion (ca. 430, 840, and 1,080 kb), and the blaVIM-2 probe hybridized with the 430- and 840-kb fragments of strain E60, indicating the chromosomal location of this gene (data not shown).

PCR amplification and sequencing with primers for the 5′ and 3′ conserved segments from class 1 integrons as previously described (9) revealed an integron almost identical to In56 previously reported in a P. aeruginosa clinical isolate (7). The only differences with In56 were those observed in the promoter region. The Pc promoter found in this P. pseudoalcaligenes E60 integron is a strong promoter (−35 [TTGACA]; −10 [TAAACT]) (2), a different configuration compared to In56 (with a weak-type promoter).

This is the first isolation of an environmental P. pseudoalcaligenes strain producing MBL. Like other species of the genus Pseudomonas (e.g., P. putida and P. stutzeri), P. pseudoalcaligenes is widely distributed in soil and aquatic habitats and rarely involved in clinical infections. It is important to note that no carbapenemase producers were detected upstream of the hospital wastewater discharge site and there were no previous recordings of Pseudomonas species, other than P. aeruginosa, infections in the hospital. Nevertheless, P. aeruginosa clinical isolates with VIM-2 were already detected in that same hospital (S. Quinteira, personal observation).

Our findings suggest that the ongoing spread of blaVIM-2 is currently occurring simultaneously in several dimensions, since it can now be found in distinct geographical locations, in several bacterial species, and in different environments. These enzymes seem not to be restricted to the hospital setting, a fact that emphasizes the importance of surveying environmental strains that might act as a source and/or reservoir of resistance genes with clinical relevance.

Nucleotide sequence accession number.

The GenBank accession no. of the nucleotide sequence reported here is AY685199 .

ACKNOWLEDGMENTS

We thank Nuno Monteiro for critical review of the manuscript.

Sandra Quinteira is a Ph.D. student from Programa PRODEP.

  • Copyright © 2005 American Society for Microbiology

REFERENCES

  1. 1.↵
    Cardoso, O., R. Leitão, A. Figueiredo, J. C. Sousa, A. Duarte, and L. Peixe. 2002. Metallo-β-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. Microb. Drug Resist.8:93-97.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Collis, C. M., and R. M. Hall. 1995. Expression of antibiotic resistance genes in the integrated cassettes of integrons. Antimicrob. Agents Chemother.39:155-162.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Galani, I., M. Souli, Z. Chryssouli, D. Katsala, and H. Giamarellou. 2004. First identification of an Escherichia coli clinical isolate producing both metallo-β-lactamase VIM-2 and extended-spectrum β-lactamase IBC-1. Clin. Microbiol. Infect.10:757-760.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Jeong, S. H., K. Lee, Y. Chong, J. H. Yum, S. H. Lee, H. J. Choi, J. M. Kim, K. H. Park, B. H. Han, S. W. Lee, and T. S. Jeong. 2003. Characterization of a new integron containing VIM-2, a metallo-β-lactamase gene cassette, in a clinical isolate of Enterobacter cloacae. J. Antimicrob. Chemother.51:397-400.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; eleventh informational supplement M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  6. 6.↵
    Nordmann, P., and L. Poirel. 2002. Emerging carbapenemases in gram-negative aerobes. Clin. Microbiol. Infect.8:321-331.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J.-D. Cavallo, and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother.44:891-897.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Quinteira, S., O. Cardoso, J. C. Sousa, and L. Peixe. 2003. Characterization of integrons carrying VIM-2 in Pseudomonas spp. from Portugal. Clin. Microbiol. Infect.9(Suppl. 1):55.
    OpenUrlPubMed
  9. 9.↵
    Quinteira, S., J. C. Sousa, and L. Peixe. 2005. Characterization of In100, a new integron carrying a metallo-β-lactamase and a carbenicillinase, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother.49:451-453.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Senda, K., Y. Harakawa, S. Ichiyama, K. Nakashima, H. Ito, S. Ohsuka, K. Shimokata, N. Kato, and M. Ohta. 1996. PCR detection of metallo-β-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum β-lactams. J. Clin. Microbiol.34:2909-2913.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Yan, J.-J., P.-R. Hsueh, W.-C. Ko, K.-T. Luh, S.-H. Tsai, H.-M. Wu, and J.-J. Wu. 2001. Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob. Agents Chemother.45:2224-2228.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Yum, J., D. Yong, K. Lee, H.-S. Kim, and Y. Chong. 2002. A new integron carrying VIM-2 metallo-β-lactamase gene cassette in a Serratia marcescens isolate. Diagn. Microbiol. Infect. Dis.42:217-219.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
First Isolation of blaVIM-2 in an Environmental Isolate of Pseudomonas pseudoalcaligenes
Sandra Quinteira, Helena Ferreira, Luísa Peixe
Antimicrobial Agents and Chemotherapy Apr 2005, 49 (5) 2140-2141; DOI: 10.1128/AAC.49.5.2140-2141.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
First Isolation of blaVIM-2 in an Environmental Isolate of Pseudomonas pseudoalcaligenes
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
First Isolation of blaVIM-2 in an Environmental Isolate of Pseudomonas pseudoalcaligenes
Sandra Quinteira, Helena Ferreira, Luísa Peixe
Antimicrobial Agents and Chemotherapy Apr 2005, 49 (5) 2140-2141; DOI: 10.1128/AAC.49.5.2140-2141.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • Nucleotide sequence accession number.
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

Pseudomonas
beta-lactamases

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596